Global Retinal Biologics Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Retinal Biologics Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Biologics are generally produced from living organisms such as microorganisms, or animal or plant cells. Retinal biologics refer to bioengineered molecules which are implanted inside the eyes in order to heal chronic retinal diseases.

Market Overview:

The latest research study on the global Retinal Biologics market finds that the global Retinal Biologics market reached a value of USD 14413.0 million in 2022. It’s expected that the market will achieve USD 28995.83 million by 2028, exhibiting a CAGR of 12.36% during the forecast period.

Licensing and cooperation agreements between major players to expand product coverage

Many companies are signing licensing and cooperation agreements to expand their products to countries around the world to meet unmet demand. For example, in August 2021, Polpharma Biologics Group announces that its joint venture company with Santo Holding, Bioeq, has submitted a biologics license application (BLA) to the US Food and Drug Administration (FDA) for their biosimilar candidate of the ophthalmological drug Ranibizumab (Lucentis®).
In order to improve the R&D pipeline portfolio, many companies have signed cooperation agreements with various other companies and universities, which are expected to promote the development of the retinal biologics market during the forecast period.

Side effects and disadvantages of retinal biologics

When retinal biologics is used to treat retinal diseases, it may produce certain side effects, which will bring challenges to its market development. Serious side effects of retinal biologics may lead to eye infection, permanent decline of vision, increase of intraocular pressure, formation or deterioration of cataract, etc. The most common side effects are red eyes, cataract, eye swelling, irritation or pain.

The economic burden of drug development for enterprises is heavy

The economic burden of the development of retinal biologics is heavy. Therefore, many companies are generally not interested in the research and development of retinal biologics. The market participants of retinal biologics are mainly concentrated in Europe and the United States, which is mainly due to the support policies of developed countries for the development of retinal biologics. Overseas policies mainly include fee reduction and exemption, financial support, R & D assistance, priority review, market exclusivity, etc., which has greatly stimulated the enthusiasm of pharmaceutical enterprises to develop retinal biologics. However, this factor will also bring challenges to its market development.

Region Overview:

In 2022, the share of the Retinal Biologics market in North America stood at 50.65%.

Company Overview:

Regeneron Pharmaceuticals, Inc is one of the major players operating in the Retinal Biologics market, holding a share of 37.8% in 2023.

Regeneron Pharmaceuticals, Inc

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.

Bayer

Bayer is a company focusing on seeds, crop protection, and non-agricultural pest control. It develops genetically modified crops and pesticides. Bayer serves customers worldwide.

Segmentation Overview:

As for product types, the Macular Degeneration segment held the largest market share in 2022.

Macular Degeneration

Macular degeneration is characterized by progressive degeneration of the macula, the central part of the retina, leading to central vision loss. The current treatment for macular degeneration is the injection of anti-VEGF medication into each affected eye. Three anti-VEGF biologics are currently available: the VEGF-decoy aflibercept (Eylea), antibody fragments ranibizumab (Lucentis), and brolucizumab (Beovu).

Diabetic Retinopathy

Diabetic retinopathy usually only requires specific treatment when it reaches an advanced stage and there's a risk to patients' vision. In some cases of diabetic maculopathy, injections of a medicine called anti-VEGF may be given directly into patients' eyes to prevent new blood vessels forming at the back of the eyes.

Diabetic Macular Edema

Diabetic macular edema (DME) is one of the main causes of visual impairment in persons with diabetic retinopathy. Owing to the efficacy and safety profile of anti-VEGF therapy, it has become the first-line treatment. Besides ranibizumab and aflibercept, bevacizumab demonstrated efficacy in the treatment of DME.

Uveitis

Uveitis is characterized by intraocular inflammation affecting the uveal structures of the eye, including the iris, ciliary body, and choroid. The success in rheumatology of the TNF-α inhibitors adalimumab (ADA) and infliximab (IFX) over the past several years has led to their use in uveitis.

Application Overview:

The market's largest segment by application is the segment Hospitals, with a market share of 68.01% in 2022.

Key Companies in the global Retinal Biologics market covered in Chapter 3:

Amgen Inc
Bayer
Johnson & Johnson Services, Inc
Regeneron Pharmaceuticals, Inc
Roche
Novartis
AbbVie Inc

In Chapter 4 and Chapter 14.2, on the basis of types, the Retinal Biologics market from 2018 to 2029 is primarily split into:

Macular Degeneration
Diabetic Retinopathy
Diabetic Macular Edema
Uveitis
Others

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Retinal Biologics market from 2018 to 2029 covers:

Hospitals
Clinics
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)